2,5- bis-(Glutathion- S-yl)-α-methyldopamine, a putative metabolite of (±)-3,4-methylenedioxyamphetamine, decreases brain serotonin concentrations

3,4-(±)-Methylenedioxyamphetamine (MDA) and 3,4-(±)-methylenedioxymethamphetamine (MDMA) are serotonergic neurotoxicants. However, when injected directly into brain, MDA and MDMA are not neurotoxic, suggesting that systemic metabolism plays an important role in the development of neurotoxicity. The...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of pharmacology 1997-04, Vol.323 (2), p.173-180
Hauptverfasser: Miller, R.Timothy, Lau, Serrine S, Monks, Terrence J
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 180
container_issue 2
container_start_page 173
container_title European journal of pharmacology
container_volume 323
creator Miller, R.Timothy
Lau, Serrine S
Monks, Terrence J
description 3,4-(±)-Methylenedioxyamphetamine (MDA) and 3,4-(±)-methylenedioxymethamphetamine (MDMA) are serotonergic neurotoxicants. However, when injected directly into brain, MDA and MDMA are not neurotoxic, suggesting that systemic metabolism plays an important role in the development of neurotoxicity. The nature of the metabolite(s) responsible for MDA- and MDMA-mediated neurotoxicity is unclear. α-Methyldopamine is a major metabolite of MDA and is readily oxidized to the o-quinone, followed by conjugation with glutathione (GSH). Because the conjugation of quinones with GSH frequently results in preservation or enhancement of biological (re)activity, we have been investigating the role of quinone-thioethers in the acute and long-term neurochemical changes observed after administration of MDA. Although intracerebroventricular (i.c.v.) administration of 5-(glutathion- S-yl)-α-methyldopamine (4×720 nmol) and 5-( N-acetylcystein- S-yl)-α-methyldopamine (1×7 nmol) to Sprague-Dawley rats produced overt behavioral changes similar to those seen following administration of MDA (93 μmol/kg, s.c.) they did not produce long-term decreases in brain serotonin (5-hydroxytryptamine, 5-HT) concentrations. In contrast, 2,5- bis-(glutathion- S-yl)-α-methyldopamine (4×475 nmol) decreased 5-HT levels by 24%, 65% and 30% in the striatum, hippocampus and cortex, respectively, 7 days after injection. The relative sensitivity of the striatum, hippocampus and cortex to 2,5- bis-(glutathion- S-yl)-α-methyldopamine was the same as that observed for MDA; the absolute effects were greater with MDA. The effects of 2,5- bis-(glutathion- S-yl)-α-methyldopamine were also selective for serotonergic nerve terminal fields, in that 5-HT levels were unaffected in regions of the cell bodies. Because 2,5- bis-(glutathion- S-yl)-α-methyldopamine caused long-term depletion in 5-HT without adversely affecting the dopaminergic system, it also mimics the selectivity of MDA/MDMA. The data imply a possible role for quinone-thioethers in the neurobehavioral and neurotoxicological effects of MDA/MDMA. © 1997 Elsevier Science B.V. All rights reserved.
doi_str_mv 10.1016/S0014-2999(97)00044-7
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_16453266</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0014299997000447</els_id><sourcerecordid>16453266</sourcerecordid><originalsourceid>FETCH-LOGICAL-c420t-cffeafbbad584f03b9e4b2d85fd5f9897a4da323e948dc96b53fb86b7cd35e823</originalsourceid><addsrcrecordid>eNqFkc2KFDEUhQtRxnb0EQZqIdINHU3lp6qyEhl0FAZcjK5Dfm7oSFVSJtWD_R6-yLyCD-AzmZ4ueuvqBs537g3nVNVVg982uGnf3WHcMESEEGvRbTDGjKHuSbVq-k4g3DXkabU6I8-rFzn_KBAXhF9UF6IhfU_bVfWbbDmqtc9ofTPsZzXvfAyovkOHYYP-PqAR5t1hsHFSow-wrVU9HSl_D3WRlI6Dn6GOrl7_edggumWLAwJYH38d1DjtCncyWzAJVIZc66R8qDOkOMdQXiYGA2FOZXMM-WX1zKkhw6tlXlbfP338dv0Z3X69-XL94RYZRvCMjHOgnNbK8p45TLUApontubPciV50illFCQXBemtEqzl1um91Zyzl0BN6Wb057Z1S_LmHPMvRZwPDoALEfZZNyzglbVtAfgJNijkncHJKflTpIBssj23IxzbkMWopOvnYhuyK72o5sNcj2LNrib_orxddZaMGl1QwPp8x0tJOtLxg708YlDDuPSSZjYeSmPUJzCxt9P_5yD_cAKqE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>16453266</pqid></control><display><type>article</type><title>2,5- bis-(Glutathion- S-yl)-α-methyldopamine, a putative metabolite of (±)-3,4-methylenedioxyamphetamine, decreases brain serotonin concentrations</title><source>Elsevier ScienceDirect Journals Complete - AutoHoldings</source><source>MEDLINE</source><creator>Miller, R.Timothy ; Lau, Serrine S ; Monks, Terrence J</creator><creatorcontrib>Miller, R.Timothy ; Lau, Serrine S ; Monks, Terrence J</creatorcontrib><description>3,4-(±)-Methylenedioxyamphetamine (MDA) and 3,4-(±)-methylenedioxymethamphetamine (MDMA) are serotonergic neurotoxicants. However, when injected directly into brain, MDA and MDMA are not neurotoxic, suggesting that systemic metabolism plays an important role in the development of neurotoxicity. The nature of the metabolite(s) responsible for MDA- and MDMA-mediated neurotoxicity is unclear. α-Methyldopamine is a major metabolite of MDA and is readily oxidized to the o-quinone, followed by conjugation with glutathione (GSH). Because the conjugation of quinones with GSH frequently results in preservation or enhancement of biological (re)activity, we have been investigating the role of quinone-thioethers in the acute and long-term neurochemical changes observed after administration of MDA. Although intracerebroventricular (i.c.v.) administration of 5-(glutathion- S-yl)-α-methyldopamine (4×720 nmol) and 5-( N-acetylcystein- S-yl)-α-methyldopamine (1×7 nmol) to Sprague-Dawley rats produced overt behavioral changes similar to those seen following administration of MDA (93 μmol/kg, s.c.) they did not produce long-term decreases in brain serotonin (5-hydroxytryptamine, 5-HT) concentrations. In contrast, 2,5- bis-(glutathion- S-yl)-α-methyldopamine (4×475 nmol) decreased 5-HT levels by 24%, 65% and 30% in the striatum, hippocampus and cortex, respectively, 7 days after injection. The relative sensitivity of the striatum, hippocampus and cortex to 2,5- bis-(glutathion- S-yl)-α-methyldopamine was the same as that observed for MDA; the absolute effects were greater with MDA. The effects of 2,5- bis-(glutathion- S-yl)-α-methyldopamine were also selective for serotonergic nerve terminal fields, in that 5-HT levels were unaffected in regions of the cell bodies. Because 2,5- bis-(glutathion- S-yl)-α-methyldopamine caused long-term depletion in 5-HT without adversely affecting the dopaminergic system, it also mimics the selectivity of MDA/MDMA. The data imply a possible role for quinone-thioethers in the neurobehavioral and neurotoxicological effects of MDA/MDMA. © 1997 Elsevier Science B.V. All rights reserved.</description><identifier>ISSN: 0014-2999</identifier><identifier>EISSN: 1879-0712</identifier><identifier>DOI: 10.1016/S0014-2999(97)00044-7</identifier><identifier>PMID: 9128836</identifier><identifier>CODEN: EJPHAZ</identifier><language>eng</language><publisher>Amsterdam: Elsevier B.V</publisher><subject>3,4-Methylenedioxyamphetamine - toxicity ; 5-HT (5-hydroxytryptamine, serotonin) ; Animals ; Behavior, Animal - drug effects ; Biological and medical sciences ; Brain - drug effects ; Brain - metabolism ; Cerebral Cortex - drug effects ; Cerebral Cortex - metabolism ; Chemical and industrial products toxicology. Toxic occupational diseases ; Corpus Striatum - drug effects ; Corpus Striatum - metabolism ; Deoxyepinephrine - analogs &amp; derivatives ; Deoxyepinephrine - toxicity ; Depression, Chemical ; Glutathione ; Glutathione - analogs &amp; derivatives ; Glutathione - toxicity ; Hippocampus - drug effects ; Hippocampus - metabolism ; Male ; MDA (3,4-Methylenedioxyamphetamine) ; MDMA (3,4-Methylenedioxymethamphetamine) ; Medical sciences ; Neurotoxicity ; Rats ; Rats, Sprague-Dawley ; Serotonin - metabolism ; Serotonin Agents - toxicity ; Toxicology ; Various organic compounds ; α-Methyldopamine</subject><ispartof>European journal of pharmacology, 1997-04, Vol.323 (2), p.173-180</ispartof><rights>1997 Elsevier Science B.V.</rights><rights>1997 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c420t-cffeafbbad584f03b9e4b2d85fd5f9897a4da323e948dc96b53fb86b7cd35e823</citedby><cites>FETCH-LOGICAL-c420t-cffeafbbad584f03b9e4b2d85fd5f9897a4da323e948dc96b53fb86b7cd35e823</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S0014-2999(97)00044-7$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,778,782,3539,27907,27908,45978</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=2637965$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9128836$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Miller, R.Timothy</creatorcontrib><creatorcontrib>Lau, Serrine S</creatorcontrib><creatorcontrib>Monks, Terrence J</creatorcontrib><title>2,5- bis-(Glutathion- S-yl)-α-methyldopamine, a putative metabolite of (±)-3,4-methylenedioxyamphetamine, decreases brain serotonin concentrations</title><title>European journal of pharmacology</title><addtitle>Eur J Pharmacol</addtitle><description>3,4-(±)-Methylenedioxyamphetamine (MDA) and 3,4-(±)-methylenedioxymethamphetamine (MDMA) are serotonergic neurotoxicants. However, when injected directly into brain, MDA and MDMA are not neurotoxic, suggesting that systemic metabolism plays an important role in the development of neurotoxicity. The nature of the metabolite(s) responsible for MDA- and MDMA-mediated neurotoxicity is unclear. α-Methyldopamine is a major metabolite of MDA and is readily oxidized to the o-quinone, followed by conjugation with glutathione (GSH). Because the conjugation of quinones with GSH frequently results in preservation or enhancement of biological (re)activity, we have been investigating the role of quinone-thioethers in the acute and long-term neurochemical changes observed after administration of MDA. Although intracerebroventricular (i.c.v.) administration of 5-(glutathion- S-yl)-α-methyldopamine (4×720 nmol) and 5-( N-acetylcystein- S-yl)-α-methyldopamine (1×7 nmol) to Sprague-Dawley rats produced overt behavioral changes similar to those seen following administration of MDA (93 μmol/kg, s.c.) they did not produce long-term decreases in brain serotonin (5-hydroxytryptamine, 5-HT) concentrations. In contrast, 2,5- bis-(glutathion- S-yl)-α-methyldopamine (4×475 nmol) decreased 5-HT levels by 24%, 65% and 30% in the striatum, hippocampus and cortex, respectively, 7 days after injection. The relative sensitivity of the striatum, hippocampus and cortex to 2,5- bis-(glutathion- S-yl)-α-methyldopamine was the same as that observed for MDA; the absolute effects were greater with MDA. The effects of 2,5- bis-(glutathion- S-yl)-α-methyldopamine were also selective for serotonergic nerve terminal fields, in that 5-HT levels were unaffected in regions of the cell bodies. Because 2,5- bis-(glutathion- S-yl)-α-methyldopamine caused long-term depletion in 5-HT without adversely affecting the dopaminergic system, it also mimics the selectivity of MDA/MDMA. The data imply a possible role for quinone-thioethers in the neurobehavioral and neurotoxicological effects of MDA/MDMA. © 1997 Elsevier Science B.V. All rights reserved.</description><subject>3,4-Methylenedioxyamphetamine - toxicity</subject><subject>5-HT (5-hydroxytryptamine, serotonin)</subject><subject>Animals</subject><subject>Behavior, Animal - drug effects</subject><subject>Biological and medical sciences</subject><subject>Brain - drug effects</subject><subject>Brain - metabolism</subject><subject>Cerebral Cortex - drug effects</subject><subject>Cerebral Cortex - metabolism</subject><subject>Chemical and industrial products toxicology. Toxic occupational diseases</subject><subject>Corpus Striatum - drug effects</subject><subject>Corpus Striatum - metabolism</subject><subject>Deoxyepinephrine - analogs &amp; derivatives</subject><subject>Deoxyepinephrine - toxicity</subject><subject>Depression, Chemical</subject><subject>Glutathione</subject><subject>Glutathione - analogs &amp; derivatives</subject><subject>Glutathione - toxicity</subject><subject>Hippocampus - drug effects</subject><subject>Hippocampus - metabolism</subject><subject>Male</subject><subject>MDA (3,4-Methylenedioxyamphetamine)</subject><subject>MDMA (3,4-Methylenedioxymethamphetamine)</subject><subject>Medical sciences</subject><subject>Neurotoxicity</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><subject>Serotonin - metabolism</subject><subject>Serotonin Agents - toxicity</subject><subject>Toxicology</subject><subject>Various organic compounds</subject><subject>α-Methyldopamine</subject><issn>0014-2999</issn><issn>1879-0712</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc2KFDEUhQtRxnb0EQZqIdINHU3lp6qyEhl0FAZcjK5Dfm7oSFVSJtWD_R6-yLyCD-AzmZ4ueuvqBs537g3nVNVVg982uGnf3WHcMESEEGvRbTDGjKHuSbVq-k4g3DXkabU6I8-rFzn_KBAXhF9UF6IhfU_bVfWbbDmqtc9ofTPsZzXvfAyovkOHYYP-PqAR5t1hsHFSow-wrVU9HSl_D3WRlI6Dn6GOrl7_edggumWLAwJYH38d1DjtCncyWzAJVIZc66R8qDOkOMdQXiYGA2FOZXMM-WX1zKkhw6tlXlbfP338dv0Z3X69-XL94RYZRvCMjHOgnNbK8p45TLUApontubPciV50illFCQXBemtEqzl1um91Zyzl0BN6Wb057Z1S_LmHPMvRZwPDoALEfZZNyzglbVtAfgJNijkncHJKflTpIBssj23IxzbkMWopOvnYhuyK72o5sNcj2LNrib_orxddZaMGl1QwPp8x0tJOtLxg708YlDDuPSSZjYeSmPUJzCxt9P_5yD_cAKqE</recordid><startdate>19970404</startdate><enddate>19970404</enddate><creator>Miller, R.Timothy</creator><creator>Lau, Serrine S</creator><creator>Monks, Terrence J</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope></search><sort><creationdate>19970404</creationdate><title>2,5- bis-(Glutathion- S-yl)-α-methyldopamine, a putative metabolite of (±)-3,4-methylenedioxyamphetamine, decreases brain serotonin concentrations</title><author>Miller, R.Timothy ; Lau, Serrine S ; Monks, Terrence J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c420t-cffeafbbad584f03b9e4b2d85fd5f9897a4da323e948dc96b53fb86b7cd35e823</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>3,4-Methylenedioxyamphetamine - toxicity</topic><topic>5-HT (5-hydroxytryptamine, serotonin)</topic><topic>Animals</topic><topic>Behavior, Animal - drug effects</topic><topic>Biological and medical sciences</topic><topic>Brain - drug effects</topic><topic>Brain - metabolism</topic><topic>Cerebral Cortex - drug effects</topic><topic>Cerebral Cortex - metabolism</topic><topic>Chemical and industrial products toxicology. Toxic occupational diseases</topic><topic>Corpus Striatum - drug effects</topic><topic>Corpus Striatum - metabolism</topic><topic>Deoxyepinephrine - analogs &amp; derivatives</topic><topic>Deoxyepinephrine - toxicity</topic><topic>Depression, Chemical</topic><topic>Glutathione</topic><topic>Glutathione - analogs &amp; derivatives</topic><topic>Glutathione - toxicity</topic><topic>Hippocampus - drug effects</topic><topic>Hippocampus - metabolism</topic><topic>Male</topic><topic>MDA (3,4-Methylenedioxyamphetamine)</topic><topic>MDMA (3,4-Methylenedioxymethamphetamine)</topic><topic>Medical sciences</topic><topic>Neurotoxicity</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><topic>Serotonin - metabolism</topic><topic>Serotonin Agents - toxicity</topic><topic>Toxicology</topic><topic>Various organic compounds</topic><topic>α-Methyldopamine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Miller, R.Timothy</creatorcontrib><creatorcontrib>Lau, Serrine S</creatorcontrib><creatorcontrib>Monks, Terrence J</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><jtitle>European journal of pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Miller, R.Timothy</au><au>Lau, Serrine S</au><au>Monks, Terrence J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>2,5- bis-(Glutathion- S-yl)-α-methyldopamine, a putative metabolite of (±)-3,4-methylenedioxyamphetamine, decreases brain serotonin concentrations</atitle><jtitle>European journal of pharmacology</jtitle><addtitle>Eur J Pharmacol</addtitle><date>1997-04-04</date><risdate>1997</risdate><volume>323</volume><issue>2</issue><spage>173</spage><epage>180</epage><pages>173-180</pages><issn>0014-2999</issn><eissn>1879-0712</eissn><coden>EJPHAZ</coden><abstract>3,4-(±)-Methylenedioxyamphetamine (MDA) and 3,4-(±)-methylenedioxymethamphetamine (MDMA) are serotonergic neurotoxicants. However, when injected directly into brain, MDA and MDMA are not neurotoxic, suggesting that systemic metabolism plays an important role in the development of neurotoxicity. The nature of the metabolite(s) responsible for MDA- and MDMA-mediated neurotoxicity is unclear. α-Methyldopamine is a major metabolite of MDA and is readily oxidized to the o-quinone, followed by conjugation with glutathione (GSH). Because the conjugation of quinones with GSH frequently results in preservation or enhancement of biological (re)activity, we have been investigating the role of quinone-thioethers in the acute and long-term neurochemical changes observed after administration of MDA. Although intracerebroventricular (i.c.v.) administration of 5-(glutathion- S-yl)-α-methyldopamine (4×720 nmol) and 5-( N-acetylcystein- S-yl)-α-methyldopamine (1×7 nmol) to Sprague-Dawley rats produced overt behavioral changes similar to those seen following administration of MDA (93 μmol/kg, s.c.) they did not produce long-term decreases in brain serotonin (5-hydroxytryptamine, 5-HT) concentrations. In contrast, 2,5- bis-(glutathion- S-yl)-α-methyldopamine (4×475 nmol) decreased 5-HT levels by 24%, 65% and 30% in the striatum, hippocampus and cortex, respectively, 7 days after injection. The relative sensitivity of the striatum, hippocampus and cortex to 2,5- bis-(glutathion- S-yl)-α-methyldopamine was the same as that observed for MDA; the absolute effects were greater with MDA. The effects of 2,5- bis-(glutathion- S-yl)-α-methyldopamine were also selective for serotonergic nerve terminal fields, in that 5-HT levels were unaffected in regions of the cell bodies. Because 2,5- bis-(glutathion- S-yl)-α-methyldopamine caused long-term depletion in 5-HT without adversely affecting the dopaminergic system, it also mimics the selectivity of MDA/MDMA. The data imply a possible role for quinone-thioethers in the neurobehavioral and neurotoxicological effects of MDA/MDMA. © 1997 Elsevier Science B.V. All rights reserved.</abstract><cop>Amsterdam</cop><pub>Elsevier B.V</pub><pmid>9128836</pmid><doi>10.1016/S0014-2999(97)00044-7</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0014-2999
ispartof European journal of pharmacology, 1997-04, Vol.323 (2), p.173-180
issn 0014-2999
1879-0712
language eng
recordid cdi_proquest_miscellaneous_16453266
source Elsevier ScienceDirect Journals Complete - AutoHoldings; MEDLINE
subjects 3,4-Methylenedioxyamphetamine - toxicity
5-HT (5-hydroxytryptamine, serotonin)
Animals
Behavior, Animal - drug effects
Biological and medical sciences
Brain - drug effects
Brain - metabolism
Cerebral Cortex - drug effects
Cerebral Cortex - metabolism
Chemical and industrial products toxicology. Toxic occupational diseases
Corpus Striatum - drug effects
Corpus Striatum - metabolism
Deoxyepinephrine - analogs & derivatives
Deoxyepinephrine - toxicity
Depression, Chemical
Glutathione
Glutathione - analogs & derivatives
Glutathione - toxicity
Hippocampus - drug effects
Hippocampus - metabolism
Male
MDA (3,4-Methylenedioxyamphetamine)
MDMA (3,4-Methylenedioxymethamphetamine)
Medical sciences
Neurotoxicity
Rats
Rats, Sprague-Dawley
Serotonin - metabolism
Serotonin Agents - toxicity
Toxicology
Various organic compounds
α-Methyldopamine
title 2,5- bis-(Glutathion- S-yl)-α-methyldopamine, a putative metabolite of (±)-3,4-methylenedioxyamphetamine, decreases brain serotonin concentrations
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T13%3A54%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=2,5-%20bis-(Glutathion-%20S-yl)-%CE%B1-methyldopamine,%20a%20putative%20metabolite%20of%20(%C2%B1)-3,4-methylenedioxyamphetamine,%20decreases%20brain%20serotonin%20concentrations&rft.jtitle=European%20journal%20of%20pharmacology&rft.au=Miller,%20R.Timothy&rft.date=1997-04-04&rft.volume=323&rft.issue=2&rft.spage=173&rft.epage=180&rft.pages=173-180&rft.issn=0014-2999&rft.eissn=1879-0712&rft.coden=EJPHAZ&rft_id=info:doi/10.1016/S0014-2999(97)00044-7&rft_dat=%3Cproquest_cross%3E16453266%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=16453266&rft_id=info:pmid/9128836&rft_els_id=S0014299997000447&rfr_iscdi=true